Skip to main content
. 2013 Oct 7;110(43):17486–17491. doi: 10.1073/pnas.1310402110

Fig. 4.

Fig. 4.

Qualification of the G6PD-deficient huRBC SCID mouse model with other antimalarial drugs. (A) A- huRBC SCID mice were treated p.o. with PQ (25 mg/kg per day for 7 d), vehicle control (PBS for 7 d), pamaquine (75 or 50 mg/kg per day for 7 d), sitamaquine (40 mg/kg per day for 7 d), tafenoquine (2.5 mg/kg per day for 3 d), chloroquine (25 mg/kg per day for 7 d), mefloquine (40 mg/kg per day for 3 d), or doxycycline (60 mg/kg per day for 7 d). The percentage of huRBCs as measured by flow cytometry at day 7 of treatment was subtracted from the percentage of huRBCs at start of treatment and then divided by percentage of huRBCs at start of treatment to determine the percent loss of huRBCs. n = 15 for PQ and vehicle control, n = 4 for other groups. (B) A- huRBC SCID mice were treated p.o. with PQ (25 mg/kg per day for 3 d), dapsone (20 mg/kg per day for 3 d), pyrimethamine (50 mg/kg per day for 3 d), or vehicle control. Percentages of huRBCs were assessed at posttreatment day 0, day 4, and day 7.